Oramed Pharmaceuticals (Seite 1565)

[occitania]

Antwort auf Beitrag Nr.: 43.771.895 von reaaalist am 31.10.12 18:58:30

Salut reaaalist


Bio steht dir gut



à bientôt
OC

[reaaalist]

Antwort auf Beitrag Nr.: 43.767.318 von occitania am 30.10.12 17:14:01

Moin Occi!

Glückwunsch du alter Börsenfuchs!
hast heute den Zehner geholt

nach News zu ORMP habe ich heute nicht gesucht!
Aber ich kann dir sagen, an der "Pille" wird fieberhaft gearbeitet

Gruß r

[occitania]

Antwort auf Beitrag Nr.: 43.767.211 von reaaalist am 30.10.12 16:51:00

Salut reaaalist

Kittel-Treffe nur alle 2 Woche.....bei mir

Meine Schäddel tut immer noch weh...

Und kömisches Geschmackt in Mund...immer noch...

Viel spass ..Heute.

à bientôt
OC

Oramed....behalte ich im Auge...

[reaaalist]

Antwort auf Beitrag Nr.: 43.767.133 von occitania am 30.10.12 16:35:31

...Ich liebe solche Wörte...

ja, ich auch Occi,

noch schöner finde ich aber die Worte, wenn eine hübsche Frau zu mir sagt:

"Willst Du mit mir schlafen?"

Gruß r

PS. bin gleich weg zum "Kittel-Treffe mit Köter"

[occitania]

Antwort auf Beitrag Nr.: 43.763.782 von reaaalist am 29.10.12 19:32:08

Salut reaaalist,salut Wanduhr


Zitat:

This study and data from our previous studies, suggests that Oramed technologies the effective and well-tolerated delivery platform research and development risks and making significant clinical effect on diabetes management is. We will with confidence in direction IND approval in the U.S. Preceding

Naja....Effective...Ich liebe solche Wörte...

@reaaalist--->Faktenthread ?

à bientôt
OC

[reaaalist]

Moin

mal was zum lesen

To spread hepatitis C primarily through blood contact propecia cost.
Posted By admin on October 28, 2012

To spread hepatitis C primarily through blood contact, including sterilized needles or medical equipment, injection or intranasal drug use or blood transfusions and medical procedures performed prior to 1992.3, 4 If you think on 16 Februaryhave exposed hepatitis C, get tested and ask treatment propecia cost .
‘The new Genesys HTA System to streamline the process set-up and offers my patients an effective way to address their menorrhagia,’said Christopher Guyer, a gynecologist at Queen Alexandra Hospital, Portsmouth.
ORMD-0801 has tolerated than a positive a positive safety profiles. No cumulative side – effects have been reported during this first study extended exposure to ORMD – 0,801th In addition was the %age of patient showing clinically relevant reductions in insulin, C – peptide is, fasting plasma glucose level and Hb1Ac still higher up in the ORMD-0801 cohort of, delivery platform compared to placebo. Moreover, mean decrease of insulin and CRP levels were found to be statistically significant for the 6-week once daily ORMD-0801 treatment. These results suggest in that ORMD-0801 dampen insulin overproduction of reprieving beta cells made their increased activity of. Reported results document the efficacy and safety of ORMD-0801 and demonstrate that oral insulin having a clinically relevant effect on to dose tested. That information collected to support the development to support the development of ORMD-0801 into the future registration trials. Harold Jacob, member Oramed Board of Directors of, said: The results of this trial once again the safety of oral of insulin installation Oramed These results indicate indicate a positive trend to efficacy of the tested orally insulin preparation. Executive Nadav Kedron, Chief by of Oramed Pharmaceuticals, added, This study and data from our previous studies, suggests that Oramed technologies the effective and well-tolerated delivery platform research and development risks and making significant clinical effect on diabetes management is. We will with confidence in direction IND approval in the U.S. Preceding. . (more…)

Quelle: http://www.kprm-prd.org/

Gruß r

PS. Meinungen

[XWanduhrX]

Tach auch Leute, bin auch noch da. Traurig ist, dass das UNIVERSALZÄPCHEN noch nicht erfunden wurde und andere Substitute einen ungemein hohen Batterieverbrauch haben...schließlich haben wir Energiekrise, aber ich glaube, dass die ORAMEDWUNDERPILLE so richtig einschlagen wird......wenn sie denn dann auf den Markt kommt. (...nur nicht Dienstags auf unserem Wochenmarkt von 09:00-18:00 Uhr...da kommt kaum Jemand und kauft die Waren)
Gruß
Wanduhr

[reaaalist]

Antwort auf Beitrag Nr.: 43.755.129 von occitania am 26.10.12 13:33:54

oh

sogar mit Bildchen

vielen Dank Occi

Gruß r

[occitania]

Antwort auf Beitrag Nr.: 43.752.288 von reaaalist am 25.10.12 19:31:28

Salut reaaalist


Habe in Faktenthread reingestellt....

à bientot
OC

[reaaalist]

Antwort auf Beitrag Nr.: 43.751.441 von occitania am 25.10.12 16:18:15

da steht wieder was mit FDA
ich lese die drei Buchstaben so gern

Oramed Pharmaceuticals' Clinical Partner for FDA Oral Insulin Trials, Medpace, Wins Award as
Top CRO in the Industry


JERUSALEM, October 25 , 2012- Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB)
(www.oramed.com), a developer of oral drug delivery systems, announced today that Medpace, the Contract Research Organization (CRO) with which Oramed will conduct its FDA-approved Phase II trials of its oral insulin candidate in the U.S., has been awarded the prestigious Eagle Award for the second year in a row. Successful oral insulin trials for the Company in the U.S. will help launch Oramed into the worldwide insulin market which saw sales quadruple in the last decade to $15.4 billion, according to IMS Health.

The Eagle Award is given by the Society for Clinical Research Sites (SCRS). The award recognizes outstanding leadership, professionalism, integrity, passion and dedication to advancing the clinical research profession. SCRS' award declared Medpace as the CRO that is, "the most desirable to work with as a clinical research study partner."

"Oramed has already been privileged to witness the level of excellence that Medpace has to offer. We are pleased to align ourselves with this industry leader who is known to implement best practices. We look forward to beginning FDA clinical trials on our oral insulin candidate with this award-winning CRO," stated Oramed CEO Nadav Kidron.

About Oramed Pharmaceuticals


Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center.Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently gearing up to enter FDA-approved Phase II clinical trials in the U.S., and with its GLP-1 analog capsule, currently entering Phase Ib/IIa trials. The company's corporate and R&D headquarters are based in Jerusalem.


The company's fact sheet can be viewed here.



For more information about the company please visit www.oramed.com.


About Medpace


Medpace was established in 1992, and has partnered with leading pharmaceutical, biotechnology, and medical device companies to bring promising new drugs to market. As a full-service CRO, Medpace combines efficient clinical trial management, comprehensive
regulatory consulting, and innovative technologies to create a customized approach that ensures powerful solutions for its partners around the globe. Learn more at www.medpace.com.


Safe Harbor for Forward-looking statements: This press release contains forward-looking statements.These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.



Company and Investor Relations Contact:
Oramed Pharmaceuticals
Aviva Sherman

USA: [phone]
Int'l: + 972-54-792-4438
Email: [e-mail]